Drug Trial Radar · NCT06465199
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
265
Planned (sponsor's estimate)
Start
May 13, 2026
Primary completion
May 2033
Study completion May 2035
Sponsor
- Lead sponsor
- Milton S. Hershey Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aminex Therapeutics, Inc.; Penn State University
- First posted
- Jun 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 26 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat. The goals of this part of the study are: * Establish a recommended dose of AMXT 1501 in combination with DFMO * Test the safety and tolerability of AMXT 1501 in combination with DFMO * To determine the activity of study treatments chosen based on: * How each subject responds to the study treatment * How long a subject lives without their disease returning/progressing
Conditions
- Atypical Teratoid/Rhabdoid Tumor
- Embryonal Tumor With Multilayered Rosettes
- Ewing Sarcoma
- Diffuse Intrinsic Pontine Glioma
- Osteosarcoma
- Neuroblastoma
- DIPG Brain Tumor
Interventions
Eflornithine (DFMO)Drug
Oral DFMO capsules
AMXT 1501 DicaprateDrug
Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 28 days
- Phase II- Number of Cohort 1 participants with progression free survival (PFS) during studyTime frame: 2 years plus 5 years follow up
- Phase II- Number of Cohort 2-4 participants with progression free survival (PFS) during studyTime frame: 2 years plus 5 years follow up
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama/Children's of Alabama
Birmingham, Alabama · Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
Connecticut Children's Hospital
Hartford, Connecticut · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Nicklaus Children's Hospital
Miami, Florida · Recruiting
Arnold Palmer Hospital for Children
Orlando, Florida · Recruiting
St. Joseph's Children's Hospital
Tampa, Florida · Recruiting
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii · Recruiting
Children's Mercy Hospitals and Clinics
Kansas City, Kansas · Recruiting
Helen DeVos Children's Hospital
Grand Rapids, Michigan · Recruiting
Cardinal Glennon Children's Medical Center
St Louis, Missouri · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania · Recruiting
Monroe Carrell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee · Recruiting
Dell Children's Blood and Cancer Center
Austin, Texas · Recruiting
Children's Medical Center
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.